First Author: T.Monteiro PORTUGAL
Co Author(s): C. Freitas F. Vaz
Purpose:
To investigate the safety and effectiveness of the AcrySof phakic angle-suppported intraocular lens (IOL) (Alcon® Laboratories, Inc., Fort Worth, TX) for correction of moderate-to-high myopia in adults after a 12 month follow-up.
Setting:
Hospital de Braga, Portugal
Methods:
12 month follow-up prospective study of 22 consecutive eyes implanted with the AcrySof phakic angle-supported IOL (placed near the 90 degree meridian) for the correction of myopia. Parameters studied: Uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA) pre and postoperative, mean manifest refraction spherical equivalent (MRSE) pre and postoperative, endothelial cell counts pre and postoperative. For purposes of IOL size selection and eligibility determination, the anterior chamber diameter was measured as the width of the cornea from nasal limbus to temporal limbus (the white-to-white) with Zeiss IOL Master (Carl Zeiss® AG, Oberkochen, Germany).
Results:
A total of 22 eyes were analysed. The preoperative mean manifest spherical error (MRSE) was -8,61 diopters (D) (SD ± 3,31). No subjects lost ?2 lines BSCVA. Mean BSCVA preoperative was 0,79 (SD ± 0,21); mean UCVA postoperative was 0,83 (SD ± 0,23), mean CDVA postoperative was 0,95 (SD ± 0,15). The overall mean percentage change in central endothelial cell density 12 months after surgery was -3,71 ± 0,82 %. No pupil ovalization, pupillary block, or retinal detachment events were observed. In the immediate postoperative period we observed one case of ocular hypertension and one case of anterior uveitis, both successfully treated with topical medications.
Conclusions:
The AcrySof phakic angle-supported IOL yielded excellent refractive correction and predictability with acceptable safety in subjects with moderate-to-high myopia. FINANCIAL DISCLOSURE?: No
Please wait while information is loading.
